Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Public ClinicalTrials.gov record NCT01314261. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Study identification
- NCT ID
- NCT01314261
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 37 participants
Conditions and interventions
Interventions
- ABT-267 Drug
- Pegylated interferon (pegIFN) Drug
- Placebo for ABT-267 Other
- Ribavirin (RBV) Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2011
- Primary completion
- Dec 31, 2011
- Completion
- Jan 31, 2013
- Last update posted
- Jul 1, 2018
2011 – 2013
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 56623 | Birmingham | Alabama | 35215 | — |
| Site Reference ID/Investigator# 48476 | Los Angeles | California | 90048 | — |
| Site Reference ID/Investigator# 51345 | Orlando | Florida | 32809 | — |
| Site Reference ID/Investigator# 51498 | Honolulu | Hawaii | 96814 | — |
| Site Reference ID/Investigator# 48473 | Indianapolis | Indiana | 46202 | — |
| Site Reference ID/Investigator# 52782 | Kansas City | Missouri | 64131 | — |
| Site Reference ID/Investigator# 48471 | Houston | Texas | 77030 | — |
| Site Reference ID/Investigator# 48474 | San Antonio | Texas | 78215 | — |
| Site Reference ID/Investigator# 48477 | Fairfax | Virginia | 22031 | — |
| Site Reference ID/Investigator# 48472 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01314261, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2018 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01314261 live on ClinicalTrials.gov.